Hepatitis C Therapy - Peregrine Announces Acceleration of Its Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program

Peregrine Announces Acceleration of Its Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program
[Press Release] PR Newswire via Yahoo! Finance - Jan 18 4:00 AM
Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for viral diseases and cancer, today announced that it has accelerated its clinical program for Tarvacin Anti-Viral for the treatment of chronic hepatitis C virus infection .Save to My Web

Keryx Biopharmaceuticals, Inc. Announces Appointment of Senior Pharmaceutical Executive to Board of Directors
[Press Release] PR Newswire via Yahoo! Finance - Jan 04 5:29 AM
Keryx Biopharmaceuticals, Inc. today announced the appointment of Jonathan Spicehandler, M.D., to the Company's Board of Directors.Save to My Web

Schering-Plough to evaluate Peg-Intron in combined disease
Pharmaceutical Business Review - Jan 16 6:10 PM
Schering-Plough is set to initiate a large multinational clinical trial to evaluate the use of low-dose Peg-Intron maintenance monotherapy in patients who are infected with both hepatitis C and HIV.Save to My Web